Keros Therapeutics (NASDAQ:KROS) Earns Buy Rating from Analysts at Guggenheim

Guggenheim began coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report issued on Monday morning, MarketBeat reports. The firm issued a buy rating and a $96.00 price target on the stock.

Several other research firms have also issued reports on KROS. HC Wainwright restated a buy rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Truist Financial reiterated a buy rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Oppenheimer started coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They set an outperform rating and a $102.00 target price for the company. Finally, Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a buy rating on the stock in a research note on Thursday, September 12th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of Buy and an average price target of $90.63.

Keros Therapeutics Trading Up 0.8 %

Keros Therapeutics stock opened at $56.88 on Monday. The company has a fifty day simple moving average of $49.80 and a 200 day simple moving average of $52.79. Keros Therapeutics has a 1-year low of $27.02 and a 1-year high of $73.00. The company has a market cap of $2.13 billion, a P/E ratio of -11.04 and a beta of 1.22.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The firm had revenue of $0.04 million during the quarter. During the same quarter last year, the firm earned ($1.27) earnings per share. On average, equities research analysts forecast that Keros Therapeutics will post -4.88 EPS for the current year.

Insider Activity

In other news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in KROS. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the 2nd quarter valued at about $128,000. Ameritas Investment Partners Inc. lifted its holdings in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares in the last quarter. Quest Partners LLC boosted its position in shares of Keros Therapeutics by 23,945.0% in the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after purchasing an additional 4,789 shares during the period. XTX Topco Ltd bought a new stake in shares of Keros Therapeutics during the 2nd quarter valued at $228,000. Finally, Bayesian Capital Management LP purchased a new position in shares of Keros Therapeutics during the 1st quarter valued at $267,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.